Importantly, MYCN-amplified tumor cells in neuroblastoma and small cell lung cancer are more sensitive to treatment with PLK1 inhibitors than tumors with normal MYCN copy number, indicating that PLK1 inhibitors are potential therapeutics for MYCN-overexpressing cancers (120). Here, PLK1 is linked to neoplasm.